Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.31 |
| ▸ | MIF | P14174 | 1/20 | 0.31 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31636273 | 0.82 | ADORA3 (0.42) | TSHRTDP1LMNAADORA3MC4R | |
| SCHEMBL19151634 | 0.82 | ADORA3 (0.42) | TSHRTDP1LMNAADORA3MC4R | |
| SCHEMBL16369768 | 0.80 | HCAR2 (0.41) | KDM4EHCAR2NAPRTALDH1A1ALOX15 | |
| SCHEMBL13086458 | 0.79 | CNR1 (0.40) | HPGD | |
| SCHEMBL27362044 | 0.79 | HCAR3 (0.35) | KDM4EHCAR2HCAR3ALOX15TSHR | |
| SCHEMBL24993310 | 0.78 | P2RX7 (0.41) | KDM4EALDH1A1GAALPAR1ADORA3 | |
| SCHEMBL69399 | 0.78 | KDM4E (0.55) | KDM4EHCAR2NAPRTALDH1A1ALOX15 | |
| SCHEMBL16431579 | 0.76 | — | — | |
| SCHEMBL1106488 | 0.75 | NOS3 (0.36) | TSHR | |
| SCHEMBL23015757 | 0.74 | CNR1 (0.45) | KDM4EALDH1A1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160272626-A1 | PYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-09-22 | — | — | US | claimed |
| EP-2917211-A1 | PYRAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2015-09-16 | — | — | EP | claimed |
| CN-104768950-A | Pyrazine derivatives | HOFFMANN LA ROCHE | 2015-07-08 | — | — | CN | claimed |
| WO-2014072257-A1 | PYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-05-15 | — | — | WO | claimed |
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED | 2018-03-01 | — | — | US | disclosed |
| US-20160272626-A1 | PYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-09-22 | — | — | US | disclosed |
| EP-2499121-B1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS. | HOFFMANN LA ROCHE (CH) | 2015-10-07 | — | — | EP | disclosed |
| EP-2917211-A1 | PYRAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2015-09-16 | — | — | EP | disclosed |
| CN-104768950-A | Pyrazine derivatives | HOFFMANN LA ROCHE | 2015-07-08 | — | — | CN | disclosed |
| WO-2014072257-A1 | PYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-05-15 | — | — | WO | disclosed |
| US-8486950-B2 | Janus kinase inhibitor compounds and methods | F. HOFFMANN-LA ROCHE AG (CH) | 2013-07-16 | — | — | US | disclosed |
| US-8354441-B2 | Oxazoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2499121-A1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS. | F. Hoffmann-La Roche AG (CH) | 2012-09-19 | — | — | EP | disclosed |
| CN-102686572-A | Oxazoline derivatives for treatment of CNS disorders | HOFFMANN LA ROCHE | 2012-09-19 | — | — | CN | disclosed |
| WO-2011057973-A1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-19 | — | — | WO | disclosed |
| US-20110112080-A1 | OXAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-12 | — | — | US | disclosed |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272626-A1 | PYRAZINE DERIVATIVES | HCRTR2, PER2, HCRTR1 | KDM4E 3624/4885HCAR2 87/4885NAPRT 2205/4885 |
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | F2RL1, PARP12, TFPI2 | KDM4E 4542/4885HCAR2 378/4885NAPRT 2290/4885 |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | KDM4E 572/4885HCAR2 1876/4885NAPRT 3358/4885 |
| US-20110112080-A1 | OXAZOLINE DERIVATIVES | TAAR1, HCRTR1, NPY1R | KDM4E 2556/4885HCAR2 380/4885NAPRT 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.